Vyas Tungaturti is a seasoned M&A operator and advisor specializing in large-scale mergers, acquisitions, and private equity due diligence. His experience spans integration and divestiture office leadership, complex cross-border transactions, and the application of AI and machine learning to deal execution. Founder of CorpDev.Org and builder of Kai, an AI due-diligence platform for deal teams, Vyas writes on deal intelligence, value creation, and how AI is reshaping M&A and PE workflows.
Genco Shipping & Trading Limited (NYSE: GNK) rejected Diana Shipping Inc.'s (NYSE: DSX) unsolicited $20.60 per share acquisition proposal and its nomination of six directors to replace Genco's...
```html TransDigm Group Incorporated has entered into a definitive agreement to acquire two private equity-backed aerospace suppliers—Jet Parts Engineering and Victor Sierra Aviation Holdings—for...
San Francisco-based Avkha Equity Holdings has acquired Minnesota-based Dart Transit, Dart Express, and their subsidiaries from the family-owned Oren family, marking a strategic entry for private...
A Trump-appointed FTC commissioner stated the agency will block mergers and acquisitions that could increase the **cost of living**, introducing a novel consumer-price lens to antitrust reviews amid...
Keurig Dr Pepper Inc. (KDP) announced a recommended public cash offer for all outstanding shares of JDE Peet's N.V. (JDEP), valuing the coffee giant at approximately €15.5 billion in a move to...
CoinGecko, the leading cryptocurrency data aggregator, is exploring a sale valued at around $500 million after 12 years as an independent company, with CEO Bobby Ong acknowledging reports and Moelis...
Oxford BioMedica PLC, a UK-based biotechnology firm specializing in viral vector manufacturing for gene therapies, has confirmed receiving an unsolicited approach from Swedish private equity giant...
Liftoff Mobile, the AI-driven performance marketing and monetization platform backed by private equity giant Blackstone, has filed for a US initial public offering, targeting a Nasdaq listing under...
Sanofi is revising its takeover offer for Ocular Therapeutix after the U.S. biotech rejected the French drugmaker's initial $16 per share proposal, according to recent filings and market reports. ...
```html Boston Scientific Acquires Penumbra In $14.5 Billion Bet To Dominate Thrombectomy body { font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', 'Helvetica Neue', sans-serif; line-height:...
